Vimarsana
Biggest News Aggregation in the World

Page 3 - John Alam News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from John Alam. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In John Alam Today - Breaking & Trending Today

EIP Pharma Announces First Patient Dosed in RewinD-LB Phase 2b Clinical Trial Evaluating Neflamapimod in Dementia with Lewy Bodies - Vimarsana News

EIP Pharma Announces First Patient Dosed in RewinD-LB Phase 2b Clinical Trial Evaluating Neflamapimod in Dementia with Lewy Bodies

/PRNewswire/ -- EIP Pharma Inc. ("EIP Pharma" or the "Company"), a privately held clinical-stage company focused on developing treatments for neurodegenerative...

Diffusion Pharmaceuticals : FORM OF PARENT STOCKHOLDER SUPPORT AGREEMENT - Form 8-K - Vimarsana News

Diffusion Pharmaceuticals : FORM OF PARENT STOCKHOLDER SUPPORT AGREEMENT - Form 8-K

FORM OF PARENT STOCKHOLDER SUPPORT AGREEMENT This Parent Stockholder Support Agreement, dated as of March 30, 2023 , by and between EIP Pharma, Inc., a Delaware corporation ,... | March 30, 2023

National Institute on Aging (NIA) awards $21M grant to support key phase 2b study of EIP Pharma's neflamapimod in dementia with Lewy bodies - Vimarsana News

National Institute on Aging (NIA) awards $21M grant to support key phase 2b study of EIP Pharma's neflamapimod in dementia with Lewy bodies

/PRNewswire/ -- EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases today announced that the National...

National Institute on Aging (NIA) awards $21M grant to support key phase 2b study of EIP Pharma's neflamapimod in dementia with Lewy bodies - Vimarsana News

National Institute on Aging (NIA) awards $21M grant to support key phase 2b study of EIP Pharma's neflamapimod in dementia with Lewy bodies

/PRNewswire/ -- EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases today announced that the National...

EIP Pharma Announces New Data Presentations from Phase 2 Treatment Trial in Dementia with Lewy Bodies at Upcoming Scientific Conference and New Board Appointment - Vimarsana News

EIP Pharma Announces New Data Presentations from Phase 2 Treatment Trial in Dementia with Lewy Bodies at Upcoming Scientific Conference and New Board Appointment

/PRNewswire/ -- EIP Pharma Inc., a clinical-stage pharma company focused on the development of disease-modifying treatments for dementia and neurodegenerative...